Key result
Cardiac Nrf2 overexpression prevents diabetic cardiomyopathy in mice by improving metabolism and reducing oxidative stress.
Why the study?
The mechanisms underlying Nrf2 cardiac protection and its direct actions on cardiomyocytes in diabetic cardiomyopathy are not well understood.
Does cardiomyocyte-specific overexpression of Nrf2 prevent diabetic cardiomyopathy in a streptozotocin-induced type 1 diabetes mouse model?
Population
Streptozotocin-induced type 1 diabetes mouse model
Comparison
Cardiomyocyte-restricted Nrf2 transgenic mice vs wild-type mice
Design
Preclinical animal study
Authors
Loading...
Does not support clinical adoption; leaves open human translation of cardiomyocyte Nrf2 activation in diabetic cardiomyopathy.
Does cardiomyocyte-specific overexpression of Nrf2 prevent diabetic cardiomyopathy in a streptozotocin-induced type 1 diabetes mouse model?
Cardiomyocyte-specific overexpression of Nrf2 protects against diabetic cardiomyopathy in mice by reducing oxidative stress and improving glucose and lipid metabolism.
Yang et al. (2024) studied Diabetic cardiomyopathy. Cardiomyocyte-specific overexpression of Nrf2 vs. Wild-type mice was evaluated on Resistance to diabetic cardiomyopathy (echocardiography, myocardial fibrosis, cardiac inflammation, oxidative stress). Cardiomyocyte-specific overexpression of Nrf2 prevented diabetic cardiomyopathy in mice by improving glucose and lipid metabolism and reducing oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: